Greiner R H, Blattmann H J, Thum P, Coray A, Crawford J F, Kann R H, Munkel G, Pedroni E, von Essen C F, Zimmermann A
Paul Scherrer Institute, Division of Radiation Medicine, Villigen-PSI, Switzerland.
Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1077-83. doi: 10.1016/0360-3016(89)90159-4.
Since November 1981, when pion irradiation was introduced for deep seated tumors at the Swiss Institute for Nuclear Research (SIN, now Paul Scherrer Institute, PSI) a dynamic, 3-dimensional spot scan treatment technique has been in use. To exploit this technique a special optimization treatment planning system has been designed. Of a total of 331 patients treated with pions from November 1981-December 1987, 35 were irradiated for unresectable soft tissue sarcomas. In 32/35 patients, tumor sites were retroperitoneal, pelvic or in the groin or thigh. Twenty-nine tumors had a maximum diameter of greater than 10 cm, 18 tumors of greater than 15 cm; 30 tumors had grade 2/3 and 32 Stage III B/IV A/IV B. Eight of 35 patients received a low pion total dose, 7-27 Gy. Twenty-seven patients received a total dose of 30-36 Gy, fraction size 150-170 cGy (90%-isodose), 20 fractions, 4 times per week. Of these 27 patients, severe late reactions appeared in five: 2/8 patients with extremity/groin sarcomas (1/2 caused by biopsy) and 3/19 patients with retroperitoneal/pelvic sarcomas (one a skin reaction after Actinomycin-D, one a small bowel reaction after 36 Gy, a dose no longer used). Seven of 27 patients had metastases at the beginning of irradiation. Three of 27 were treated with excisional biopsy, 9 with incisional biopsy or partial resection and in 15 patients biopsies were performed for histology only. The median follow-up of these 27 patients was 17 months (5-66). There was no progression in eight extremity/groin tumors but in 4 of 19 retroperitoneal/pelvic tumors. Three of these were marginal progressions. The actuarial 5-year rate of local tumor control is 64%; the actuarial 5-year survival rate of patients without metastases at the beginning of treatment is 58%. Dynamic spot scan pion irradiation proves to be a successful treatment technique for unresectable sarcomas with a high rate of tumor control and a very low rate of severe late reactions.
自1981年11月瑞士核研究所(SIN,现为保罗·谢勒研究所,PSI)开始将π介子照射用于深部肿瘤治疗以来,一种动态三维点扫描治疗技术一直在使用。为利用这一技术,设计了一种特殊的优化治疗计划系统。在1981年11月至1987年12月期间接受π介子治疗的331例患者中,35例因不可切除的软组织肉瘤接受了照射。在35例患者中的32例中,肿瘤部位位于腹膜后、盆腔或腹股沟或大腿。29个肿瘤最大直径大于10cm,18个肿瘤大于15cm;30个肿瘤为2/3级,32个处于ⅢB/ⅣA/ⅣB期。35例患者中有8例接受了低剂量的π介子总剂量,7 - 27Gy。27例患者接受了30 - 36Gy的总剂量,分次剂量为150 - 170cGy(90%等剂量线),分20次,每周4次。在这27例患者中,5例出现了严重的晚期反应:2/8例肢体/腹股沟肉瘤患者(1/2例由活检引起)和3/19例腹膜后/盆腔肉瘤患者(1例为放线菌素-D后的皮肤反应,1例为36Gy后的小肠反应,该剂量已不再使用)。27例患者中有7例在照射开始时已有转移。27例中有3例接受了切除活检,9例接受了切开活检或部分切除,15例患者仅为进行组织学检查而进行了活检。这27例患者的中位随访时间为17个月(5 - 66个月)。8例肢体/腹股沟肿瘤无进展,但19例腹膜后/盆腔肿瘤中有4例出现进展。其中3例为边缘性进展。局部肿瘤控制的精算5年率为64%;治疗开始时无转移患者的精算5年生存率为58%。动态点扫描π介子照射被证明是一种成功的治疗不可切除肉瘤的技术,肿瘤控制率高,严重晚期反应率极低。